Ratings by BofA Securities (Greg Harrison)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/5/2026 | Liquidia Technologies | LQDA | Maintain | Buy (N/A) |
|
Details | ||
| 2/25/2026 | United Therapeutics Corp. | UTHR | Maintain | Neutral (N/A) |
|
Details | ||
| 12/26/2025 | Agios Pharma | AGIO | Maintain | Buy (N/A) |
|
Details | ||
| 11/19/2025 | Agios Pharma | AGIO | Maintain | Buy (N/A) |
|
Details | ||
| 11/3/2025 | Liquidia Technologies | LQDA | Maintain | Buy (N/A) |
|
Details | ||
| 10/31/2025 | Intellia Therapeutics | NTLA | Downgrade | Neutral (Buy) |
12.27 (13.44) |
9.54% | Details | |
| 10/27/2025 | Intellia Therapeutics | NTLA | Maintain | Buy (N/A) |
|
Details | ||
| 9/4/2025 | Agios Pharma | AGIO | Maintain | Buy (N/A) |
|
Details | ||
| 8/5/2025 | Agios Pharma | AGIO | Maintain | Buy (N/A) |
|
Details | ||
| 7/25/2025 | Rocket Pharmaceuticals | RCKT | Downgrade | Neutral (Buy) |
3.21 (2.91) |
-9.35% | Details | |
| 5/29/2025 | Intellia Therapeutics | NTLA | Maintain | Buy (N/A) |
|
Details | ||
| 5/28/2025 | Rocket Pharmaceuticals | RCKT | Maintain | Buy (N/A) |
|
Details | ||
| 5/27/2025 | Rocket Pharmaceuticals | RCKT | Maintain | Buy (N/A) |
|
Details | ||
| 5/1/2025 | United Therapeutics Corp. | UTHR | Maintain | Neutral (N/A) |
|
Details | ||
| 4/21/2025 | United Therapeutics Corp. | UTHR | Upgrade | Neutral (Underperform) |
284.73 (478.16) |
67.93% | Details | |
| 3/28/2025 | Beam Therapeutics Inc | BEAM | Upgrade | Buy (Neutral) |
22.19 (26.54) |
19.6% | Details | |
| 3/13/2025 | Mineralys Therapeutics, Inc. | MLYS | Maintain | Buy (N/A) |
|
Details | ||
| 2/11/2025 | Agios Pharma | AGIO | Maintain | Buy (N/A) |
|
Details | ||
| 1/10/2025 | Intellia Therapeutics | NTLA | Maintain | Buy (N/A) |
|
Details | ||
| 9/27/2024 | Travere Therapeutics | TVTX | Maintain | Buy (N/A) |
|
Details | ||
| 9/6/2024 | Travere Therapeutics | TVTX | Maintain | Buy (N/A) |
|
Details | ||
| 8/20/2024 | Liquidia Technologies | LQDA | Maintain | Buy (N/A) |
|
Details | ||
| 8/8/2024 | Editas Medicine | EDIT | Upgrade | Buy (Neutral) |
4.11 (2.37) |
-42.34% | Details | |
| 6/27/2024 | United Therapeutics Corp. | UTHR | Maintain | Underperform (N/A) |
|
Details | ||
| 3/14/2024 | Liquidia Technologies | LQDA | Maintain | Buy (N/A) |
|
Details | ||
| 12/21/2023 | Liquidia Technologies | LQDA | Maintain | Buy (N/A) |
|
Details | ||
| 12/15/2023 | Beam Therapeutics Inc | BEAM | Downgrade | Neutral (Buy) |
29.79 (22.19) |
-25.51% | Details | |
| 8/3/2023 | United Therapeutics Corp. | UTHR | Maintain | Underperform (N/A) |
|
Details | ||
| 7/17/2023 | Travere Therapeutics | TVTX | Maintain | Buy (N/A) |
|
Details | ||
| 6/27/2023 | Agios Pharma | AGIO | Maintain | Buy (N/A) |
|
Details | ||
| 5/15/2023 | Beam Therapeutics Inc | BEAM | Maintain | Buy (N/A) |
|
Details | ||
| 5/15/2023 | Beam Therapeutics Inc | BEAM | Maintain | Buy (N/A) |
|
Details | ||
| 5/5/2023 | Agios Pharma | AGIO | Maintain | Buy (N/A) |
|
Details | ||
| 5/4/2023 | United Therapeutics Corp. | UTHR | Maintain | Underperform (N/A) |
|
Details | ||
| 5/1/2023 | Stoke Therapeutics | STOK | Upgrade | Neutral (Underperform) |
8.89 (35.48) |
299.1% | Details | |
| 3/29/2023 | BridgeBio Pharma | BBIO | Maintain | Buy (N/A) |
|
Details | ||
| 3/7/2023 | Mineralys Therapeutics, Inc. | MLYS | New Coverage | Buy (N/A) |
18.96 (26.59) |
40.24% | Details | |
| 1/6/2023 | Alector Inc. | ALEC | Downgrade | Neutral (Buy) |
8.76 (2.00) |
-77.17% | Details | |
| 1/6/2023 | Stoke Therapeutics | STOK | Downgrade | Underperform (Buy) |
9.32 (35.48) |
280.69% | Details | |
| 12/23/2022 | Rocket Pharmaceuticals | RCKT | Maintain | Buy (N/A) |
|
Details | ||
| 11/18/2022 | Editas Medicine | EDIT | Maintain | Neutral (N/A) |
|
Details | ||
| 11/4/2022 | Intellia Therapeutics | NTLA | Maintain | Buy (N/A) |
|
Details | ||
| 10/14/2022 | Travere Therapeutics | TVTX | Maintain | Buy (N/A) |
|
Details | ||
| 9/29/2022 | Senti Biosciences, Inc. | SNTI | New Coverage | Buy (N/A) |
1.40 (0.96) |
-31.43% | Details | |
| 9/29/2022 | Editas Medicine | EDIT | New Coverage | Neutral (N/A) |
13.40 (2.00) |
-85.07% | Details | |
| 9/12/2022 | Neoleukin Therapeutics | NLTX | Downgrade | Underperform (Buy) |
1.09 (3.49) |
220.18% | Details | |
| 9/2/2022 | Liquidia Technologies | LQDA | Maintain | Buy (N/A) |
|
Details | ||
| 8/30/2022 | Liquidia Technologies | LQDA | Maintain | Buy (N/A) |
|
Details | ||
| 7/20/2022 | Liquidia Technologies | LQDA | Maintain | Buy (N/A) |
|
Details | ||
| 7/8/2022 | Alector Inc. | ALEC | Maintain | Buy (N/A) |
|
Details | ||
| 6/16/2022 | Intellia Therapeutics | NTLA | New Coverage | Buy (N/A) |
40.93 (12.27) |
-70.02% | Details | |
| 6/8/2022 | Radius Health | RDUS | Upgrade | Neutral (Underperform) |
7.10 (30.00) |
322.54% | Details | |
| 6/8/2022 | Iveric Bio | ISEE | New Coverage | Buy (N/A) |
10.98 (39.95) |
263.84% | Details | |
| 5/26/2022 | Liquidia Technologies | LQDA | New Coverage | Buy (N/A) |
3.65 (36.03) |
887.12% | Details | |
| 5/23/2022 | Athersys | ATHX | Downgrade | Underperform (Neutral) |
0.26 (0.10) |
-61.54% | Details | |
| 5/20/2022 | Rocket Pharmaceuticals | RCKT | Maintain | Buy (N/A) |
|
Details | ||
| 4/18/2022 | Nektar Therapeutics | NKTR | Maintain | Underperform (N/A) |
|
Details | ||
| 3/16/2022 | Stoke Therapeutics | STOK | Maintain | Buy (N/A) |
|
Details | ||
| 3/16/2022 | Athersys | ATHX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/15/2022 | Neoleukin Therapeutics | NLTX | Maintain | Buy (N/A) |
|
Details | ||
| 3/14/2022 | Nektar Therapeutics | NKTR | Downgrade | Underperform (Neutral) |
10.63 (70.70) |
565.1% | Details | |
| 2/25/2022 | Rocket Pharmaceuticals | RCKT | Maintain | Buy (N/A) |
|
Details | ||
| 1/13/2022 | Agios Pharma | AGIO | Maintain | Buy (N/A) |
|
Details | ||
| 1/11/2022 | Beam Therapeutics Inc | BEAM | Maintain | Buy (N/A) |
|
Details | ||
| 12/3/2021 | Radius Health | RDUS | New Coverage | Underperform (N/A) |
16.07 (30.00) |
86.68% | Details | |
| 12/3/2021 | Agios Pharma | AGIO | New Coverage | Buy (N/A) |
34.81 (27.48) |
-21.06% | Details | |
| 12/3/2021 | Stoke Therapeutics | STOK | New Coverage | Buy (N/A) |
23.85 (35.48) |
48.76% | Details | |
| 11/19/2021 | Athersys | ATHX | Downgrade | Neutral (Buy) |
1.12 (0.10) |
-91.07% | Details | |
| 10/29/2021 | Travere Therapeutics | TVTX | Maintain | Buy (N/A) |
|
Details | ||
| 9/10/2021 | Nektar Therapeutics | NKTR | New Coverage | Neutral (N/A) |
15.78 (70.70) |
348.04% | Details | |
| 9/10/2021 | Beam Inc | BEAM | New Coverage | Buy (N/A) |
108.00 (26.54) |
-75.43% | Details | |
| 8/17/2021 | Rocket Pharmaceuticals | RCKT | Maintain | Buy (N/A) |
|
Details | ||
| 8/6/2021 | Neoleukin Therapeutics | NLTX | Maintain | Buy (N/A) |
|
Details | ||
| 5/26/2021 | Travere Therapeutics | TVTX | Maintain | Buy (N/A) |
|
Details | ||
| 6/25/2020 | Rocket Pharmaceuticals | RCKT | New Coverage | Buy (N/A) |
21.31 (3.21) |
-84.94% | Details | |
| 6/25/2020 | Athersys | ATHX | New Coverage | Buy (N/A) |
2.22 (0.10) |
-95.5% | Details |
